Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Aytu Biopharma (AYTU) over the last 9 years, with Q4 2025 value amounting to -$1.1 million.

  • Aytu Biopharma's Change in Account Payables rose 4029.77% to -$1.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$384000.0, marking a year-over-year decrease of 11658.75%. This contributed to the annual value of $287000.0 for FY2025, which is 11382.47% up from last year.
  • Aytu Biopharma's Change in Account Payables amounted to -$1.1 million in Q4 2025, which was up 4029.77% from $1.7 million recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's Change in Account Payables peaked at $6.6 million during Q4 2021, and registered a low of -$9.9 million during Q3 2021.
  • Moreover, its 5-year median value for Change in Account Payables was $266000.0 (2024), whereas its average is -$328450.0.
  • As far as peak fluctuations go, Aytu Biopharma's Change in Account Payables soared by 37550.58% in 2021, and later tumbled by 117462.69% in 2025.
  • Over the past 5 years, Aytu Biopharma's Change in Account Payables (Quarter) stood at $6.6 million in 2021, then plummeted by 167.24% to -$4.4 million in 2022, then rose by 9.42% to -$4.0 million in 2023, then soared by 54.74% to -$1.8 million in 2024, then surged by 40.3% to -$1.1 million in 2025.
  • Its Change in Account Payables was -$1.1 million in Q4 2025, compared to $1.7 million in Q3 2025 and -$1.4 million in Q2 2025.